



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,

Washington, D.C. 20231 on May 9, 2002.

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney

COPY OF PAPERS  
ORIGINALLY FILED

COPY OF PAPERS  
ORIGINALLY FILED

MAY 21 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

ART UNIT 1615

Patent Application

Docket No. SPO-113

Serial No. 09/763,586

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1615

Applicant(s) : Kenji Kadomatsu, Mitsuru Horiba, Takashi Muramatsu, Shinya Ikematsu, Sadatoshi Sakuma

Serial No. : 09/763,586

Conf. No. : 7871

Filed : February 22, 2001

For: Pharmaceutical Compositions For the Prevention and Treatment of Atherosclerosis and Restenosis After PTCA

Assistant Commissioner for Patents

Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited documents is enclosed.

The undersigned hereby certifies that the items of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

The applicants wish to point out that two of these items are in a foreign language. They are as follows:

- 1) JP 07-009641 A is in Japanese. Enclosed is an English translation of the abstract and a copy of a corresponding U.S. Patent (U.S. Patent No. 5,521,001); and
- 2) WO 99/38971 is in Japanese but has an English abstract.

Also enclosed is a copy of the European Search Report wherein these references were cited. The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone No.: 352-375-8100  
Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/la

Enclosure(s): Form PTO-1449;  
Copy of references cited therein; and  
Copy of International Search Report